ADHD & Focus Issues FAQs

ADHD & Focus Issues — Top 50 Frequently Asked Questions

Evidence-based answers to the 50 most-asked questions about Attention-Deficit/Hyperactivity Disorder (ADHD), executive dysfunction, and focus issues across the lifespan. Every answer is backed by peer-reviewed scientific sources (DSM-5-TR, Lancet Psychiatry, JAMA Psychiatry, Cochrane reviews, MTA Study, APA, CHADD, and leading researchers including Russell Barkley, Stephen Faraone, Samuele Cortese, Edward Hallowell, Thomas Brown, J. Russell Ramsay, and Mary Solanto). In-text superscript numbers link to the full reference list at the bottom of this page.

Jump to a section:
1. Understanding ADHD
2. Diagnosis & Assessment
3. Medication
4. Therapy & Coaching
5. Daily Life & Strategies
6. Special Topics & Lifespan
📚 References

1. Understanding ADHD: What it is & isn’t

1. What is ADHD and what are the three presentations (inattentive, hyperactive-impulsive, combined)?

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.1 The DSM-5-TR recognizes three presentations: predominantly inattentive (≥6 inattention symptoms), predominantly hyperactive-impulsive (≥6 hyperactive-impulsive symptoms), and combined (both criteria met).1,2 Symptoms must be present before age 12, occur in two or more settings, and cause clinically significant impairment.1,3 Worldwide prevalence is approximately 5–7% in children and 2.5–4% in adults.4,5

2. What causes ADHD — is it genetic, environmental, or both?

ADHD is highly heritable, with twin studies showing heritability estimates of approximately 74–77%, making it one of the most genetically influenced psychiatric conditions.6,7 Genome-wide association studies have identified multiple risk loci involving dopamine, serotonin, and synaptic genes.8 Environmental contributors include prenatal exposure to alcohol, tobacco, and certain toxins; low birth weight; preterm birth; and severe early adversity.9,10 Neuroimaging shows differences in prefrontal cortex, basal ganglia, and cerebellar volumes, plus altered dopaminergic and noradrenergic signaling.11,12 Parenting style and screen time do not cause ADHD, though they can affect symptom expression.13

3. Is ADHD a real medical/neurological condition or is it overdiagnosed?

ADHD is recognized as a valid neurodevelopmental disorder by the WHO (ICD-11), APA (DSM-5-TR), NIMH, NICE, and the World Federation of ADHD, with consistent neurobiological, genetic, and clinical evidence.1,14,15 A 2021 international consensus statement signed by 80 leading researchers concluded that ADHD is a real disorder with clear evidence of brain-based differences and significant impairment when untreated.15 Diagnosis rates vary by country and clinician training; some studies show under-diagnosis (especially in girls, women, and minorities) and some show over-diagnosis in specific populations.16,17 When diagnosed using validated criteria, ADHD shows strong reliability and stability.15

4. What are the core symptoms of ADHD in adults vs children?

In children, ADHD often presents with overt hyperactivity, impulsivity, fidgeting, and difficulty sitting still in classrooms.1,18 In adults, hyperactivity often shifts to inner restlessness, while inattention, disorganization, time blindness, procrastination, emotional dysregulation, and poor working memory dominate.19,20 Adults frequently report difficulty starting and finishing tasks, losing things, missing deadlines, relationship friction, and chronic underachievement relative to ability.20,21 The DSM-5-TR requires ≥5 symptoms (rather than 6) for adult diagnosis.1

5. How is ADHD different from normal distractibility, laziness, or low motivation?

ADHD is a disorder of performance, not knowledge — people with ADHD know what to do but struggle to do it consistently.19,22 Russell Barkley reframes ADHD as a disorder of self-regulation involving deficits in inhibition, working memory, time-management, emotional control, and goal-directed persistence.19 Unlike everyday distractibility, ADHD symptoms are pervasive (across settings), chronic (years), early-onset (before age 12), and cause measurable impairment in academic, occupational, or social functioning.1,23 “Laziness” framings ignore that ADHD brains have documented differences in dopamine signaling and reward processing that make low-stimulation tasks neurologically harder.12,24

6. What is “executive dysfunction” and how does it relate to ADHD?

Executive functions are top-down cognitive processes managed largely by the prefrontal cortex, including working memory, inhibitory control, cognitive flexibility, planning, organization, task initiation, and self-monitoring.25,26 Thomas Brown’s model describes ADHD as primarily a developmental impairment of executive function with six clusters: activation, focus, effort, emotion, memory, and action.22 Neuroimaging confirms reduced activation in fronto-striatal and fronto-parietal networks during executive tasks in ADHD.11,27 Executive dysfunction explains why people with ADHD can be highly intelligent yet struggle with everyday tasks.22,25

7. What is “time blindness” in ADHD?

Time blindness refers to a difficulty perceiving the passage of time, estimating durations, and projecting oneself into future time horizons — a hallmark of ADHD identified by Russell Barkley.19,28 Functional MRI studies show reduced activation in cerebellum, basal ganglia, and prefrontal areas during time-estimation tasks in ADHD.29 Behaviorally, this manifests as chronic lateness, missed deadlines, poor planning for future events, “now vs not-now” thinking, and difficulty waiting.19,30 External structures (visible timers, calendars, alarms, body-doubling) compensate for the impaired internal clock.30,31

8. What is “rejection sensitive dysphoria” (RSD) and is it part of ADHD?

Rejection Sensitive Dysphoria (RSD) is an intense, often disabling emotional response to perceived or actual rejection, criticism, or failure, popularized by William Dodson but not formally listed in the DSM-5-TR.32,1 It overlaps with the well-documented emotional dysregulation/emotional impulsivity component of ADHD, which Barkley identifies as a core feature affecting up to 70% of adults with ADHD.33,34 Studies show ADHD is associated with heightened amygdala reactivity and reduced top-down regulation of emotional responses.35,36 While “RSD” is a useful clinical descriptor, treatment targets the underlying emotional dysregulation through medication (especially stimulants and guanfacine) and CBT/DBT skills.32,37

9. What is “hyperfocus” and why do people with ADHD experience it?

Hyperfocus is a state of intense, prolonged concentration on tasks that are highly stimulating, novel, interesting, or rewarding — sometimes lasting hours and excluding awareness of time, hunger, or surroundings.38,39 Despite seeming paradoxical, it fits the ADHD model of dysregulated attention: ADHD brains show altered reward and dopamine signaling, so high-stimulation tasks can over-engage attention while low-stimulation tasks under-engage it.12,40 A 2019 review confirmed hyperfocus occurs across ADHD, autism, and even neurotypical individuals, but is reported more frequently and intensely in ADHD.39 It can be a strength (deep work, creativity) or a liability (missed obligations, neglected self-care).38

2. Diagnosis & Assessment

10. How is ADHD diagnosed in adults?

Adult ADHD diagnosis requires a comprehensive clinical assessment using DSM-5-TR or ICD-11 criteria: ≥5 symptoms of inattention and/or hyperactivity-impulsivity persistent for ≥6 months, several symptoms before age 12, present in two or more settings, and causing significant impairment.1,14 Best-practice assessment includes a structured clinical interview (e.g., DIVA-5, ACE+), validated rating scales (ASRS, CAARS, BAARS-IV), collateral history from family/partner when possible, review of academic/work records, and screening for comorbid and differential diagnoses.41,42,43 Neuropsychological testing is supportive but not required for diagnosis.44

11. What ADHD screening tests and rating scales are used (ASRS, Conners, BRIEF)?

The Adult ADHD Self-Report Scale (ASRS-v1.1) developed with the WHO is a 6-item screener with strong sensitivity/specificity.45 The Conners’ Adult ADHD Rating Scales (CAARS) and Barkley Adult ADHD Rating Scale-IV (BAARS-IV) are validated, multi-dimensional measures.41,46 For children, the Vanderbilt, Conners-3, and SNAP-IV are widely used.47,48 The BRIEF measures executive function in everyday life.49 These are screening/rating tools — they support but do not replace a clinical diagnostic interview.41,43

12. Can you have ADHD without hyperactivity?

Yes — the predominantly inattentive presentation (formerly “ADD”) features inattention, distractibility, forgetfulness, disorganization, and slow processing without significant hyperactivity-impulsivity.1,50 This presentation is more common in girls, women, and adults, and is more often missed because behavior is internalizing rather than disruptive.51,52 A subset of inattentive cases shows a distinct profile termed “Sluggish Cognitive Tempo” or “Cognitive Disengagement Syndrome,” characterized by daydreaming, mental fogginess, and slow tempo.53,54

13. Why is ADHD often missed in women and girls?

Girls and women are 2–3 times less likely to be diagnosed than boys and men, despite comparable underlying prevalence in adulthood.55,56 Reasons include higher rates of inattentive (rather than hyperactive) presentation, social camouflaging/masking, internalizing symptoms (anxiety, depression) that mask ADHD, and gender bias in referral.51,57,58 Hormonal fluctuations across the menstrual cycle, pregnancy, postpartum, and perimenopause can intensify symptoms, and many women are first diagnosed in their 30s–50s after children are diagnosed or after life demands exceed compensatory strategies.59,60 Untreated ADHD in women is associated with increased risk of depression, anxiety, eating disorders, and self-harm.56,61

14. Can ADHD be diagnosed in adulthood if it wasn’t caught in childhood?

Yes — DSM-5-TR explicitly allows adult diagnosis provided several symptoms were present before age 12, even if formal diagnosis was missed.1 Retrospective evidence (school report cards, parent/sibling recall, childhood photos/journals) helps establish age of onset.41,43 Many adults compensate during structured childhood years and only present for diagnosis when adult demands (career, parenting, executive function load) overwhelm coping strategies.20,62 Adult diagnosis followed by treatment significantly improves quality of life, occupational outcomes, and mental health.63,64

15. What conditions commonly co-occur with ADHD (anxiety, depression, learning disabilities, autism)?

ADHD has high comorbidity rates: ~50% have an anxiety disorder, ~40% have a mood disorder (especially depression), ~25–45% have a learning disability, ~30–50% have oppositional defiant disorder (children), 15–25% meet criteria for substance use disorder, and 30–50% co-occur with autism spectrum disorder.65,66,67,68 Sleep disorders (insomnia, delayed sleep phase, restless legs) affect up to 70% of ADHD patients.69 Comprehensive assessment screens for all of these and treatment plans address comorbidities concurrently.14,41

16. Can trauma, anxiety, or depression mimic ADHD symptoms?

Yes — anxiety, depression, PTSD, sleep deprivation, thyroid dysfunction, and substance use can all produce inattention and concentration problems that resemble ADHD.70,71 Differential diagnosis requires careful history: ADHD onset before age 12 and pervasive across settings; trauma/anxiety/depression typically have identifiable onset and fluctuate with mood/situation.1,72 ADHD and trauma/anxiety frequently co-exist (especially in women and minorities), and treating only one while missing the other leads to poor outcomes.73,74

17. Is “adult-onset” ADHD a real thing?

Some studies have suggested cases of “adult-onset” ADHD without childhood symptoms, but most experts conclude these reflect missed childhood diagnoses, late symptom emergence under increased demands, or differential diagnoses (anxiety, depression, substance use, sleep disorders) rather than true adult-onset ADHD.75,76,15 The 2021 World Federation consensus statement concluded that ADHD is a neurodevelopmental disorder beginning in childhood, with apparent adult-onset cases nearly always reflecting prior unrecognized symptoms.15

3. Medication & Pharmacological Treatment

18. What medications are used to treat ADHD (stimulants vs non-stimulants)?

FDA-approved ADHD medications fall into two main classes: stimulants (methylphenidate-based: Ritalin, Concerta, Focalin; amphetamine-based: Adderall, Vyvanse, Dexedrine) and non-stimulants (atomoxetine/Strattera, viloxazine/Qelbree, guanfacine/Intuniv, clonidine/Kapvay).77,78 Stimulants increase synaptic dopamine and norepinephrine in the prefrontal cortex.79 Non-stimulants work via selective norepinephrine reuptake inhibition (atomoxetine, viloxazine) or alpha-2 adrenergic agonism (guanfacine, clonidine).78 Choice depends on age, comorbidities, side-effect profile, abuse risk, and response.14,80

19. How effective is ADHD medication — what does the research show?

A 2018 Lancet Psychiatry network meta-analysis by Cortese and colleagues including 133 randomized trials and 14,346 participants found that stimulants are the most effective treatment for ADHD in both children and adults, with effect sizes (SMD) of approximately 0.78–0.99 for symptom reduction.81 The landmark MTA Study (Multimodal Treatment of ADHD) showed combined medication + behavioral therapy outperformed either alone for symptom reduction.82,83 Long-term observational data show medication is associated with reduced risks of motor vehicle crashes, criminality, substance use, suicide, and accidents.84,85,86

20. Are stimulant medications addictive or dangerous long-term?

When prescribed and taken as directed, stimulant medications for ADHD are not associated with increased risk of substance use disorder; in fact, treatment is associated with lower rates of subsequent substance abuse compared to untreated ADHD.87,88 Long-term cardiovascular safety studies in millions of patients show no increased risk of serious cardiovascular events at therapeutic doses, though modest increases in heart rate and blood pressure require monitoring.89,90 Misuse risk exists primarily with diversion (sharing/selling) and supratherapeutic non-oral routes; formulations like Vyvanse (lisdexamfetamine) have lower abuse liability due to enzymatic activation.91

21. What are the side effects of ADHD medications?

Common stimulant side effects include decreased appetite, weight loss, insomnia, headache, dry mouth, increased heart rate/blood pressure, irritability when wearing off (“rebound”), and emotional flatness at high doses.81,92 Less common: tics, anxiety, mood changes, and (rarely) growth slowing in children that typically reverses on discontinuation.93,94 Atomoxetine can cause GI upset, fatigue, dizziness, and rare hepatotoxicity.95 Guanfacine can cause sedation, dizziness, and hypotension.96 Most side effects are mild, dose-related, and manageable through dose adjustments, timing changes, or formulation switches.14,80

22. What’s the difference between Adderall, Ritalin, Vyvanse, and Concerta?

Ritalin/Concerta contain methylphenidate; Ritalin IR is short-acting (3–4h), Concerta is long-acting (10–12h via OROS technology).97 Adderall is a mix of amphetamine salts (IR ~4–6h; XR ~10–12h).98 Vyvanse (lisdexamfetamine) is a prodrug requiring enzymatic conversion to dextroamphetamine, providing smooth ~12–14h coverage with lower abuse liability.91,99 Methylphenidate and amphetamine work through partially distinct mechanisms; meta-analyses suggest amphetamines have slightly larger effect sizes in adults, methylphenidate in children, but individual response varies and trial-and-error is common.81,100

23. What non-stimulant options exist (atomoxetine, guanfacine, clonidine, viloxazine)?

Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor with effect sizes ~0.6, taking 4–6 weeks for full effect; useful when stimulants are contraindicated or in patients with anxiety or substance use risk.95,101 Guanfacine ER (Intuniv) and clonidine ER (Kapvay) are alpha-2 agonists, particularly helpful for hyperactivity, impulsivity, emotional dysregulation, sleep, and tic disorders.96,102 Viloxazine ER (Qelbree), FDA-approved 2021–2022, is a serotonin-norepinephrine modulator with proven efficacy in children and adults.103 Bupropion and modafinil are sometimes used off-label.104

24. Can you take ADHD medication during pregnancy or while breastfeeding?

Decisions about ADHD medication in pregnancy require individualized risk-benefit analysis with an obstetrician and psychiatrist. Large register-based studies show no robust evidence of major teratogenic effects from methylphenidate or amphetamines, though some studies suggest small increases in cardiac malformations or pregnancy complications.105,106 Untreated severe ADHD also carries risks (accidents, missed prenatal care, depression).107 Stimulants pass into breast milk in small amounts; many clinicians consider them compatible with breastfeeding with monitoring.108 Guidance from professional bodies (NICE, CANMAT, ACOG) recommends shared decision-making.14,109

25. Should children take ADHD medication — are there long-term risks?

Multiple long-term studies, including the MTA follow-ups (16+ years) and Swedish/Danish national registries, show that ADHD medication is associated with improvements in academics, relationships, accident rates, criminality, and substance use.82,84,86 Concerns about growth slowing show small effects (~1–3 cm at end of growth) that mostly normalize after discontinuation, with no significant impact on final adult height in most patients.93,110 AAP, NICE, and CADDRA guidelines support medication as first-line for moderate-severe ADHD ≥6 years, combined with behavioral approaches.111,14,112

26. What should I do if my ADHD medication isn’t working?

Roughly 30% of patients don’t respond optimally to the first stimulant; switching class (methylphenidate ↔ amphetamine) or dose often resolves this.81,100 Other steps: re-evaluate for missed comorbidities (anxiety, depression, sleep disorder, substance use, thyroid), check sleep/exercise/nutrition, address timing or formulation issues (booster doses, longer-acting versions), screen for stimulant tolerance (rare), consider non-stimulant augmentation, and add behavioral/coaching interventions.14,113 Persistent non-response warrants comprehensive re-assessment by an ADHD specialist.43

4. Therapy, Coaching & Behavioral Interventions

27. Does therapy work for ADHD without medication?

Therapy alone is less effective than medication for core ADHD symptoms but is essential for managing functional impairment, comorbid conditions, and learned coping patterns.81,114 CBT for ADHD shows medium-to-large effect sizes for improving executive function, organization, time management, and emotional regulation, especially when combined with medication.114,115 Patients who decline or cannot tolerate medication, or who have mild ADHD, often benefit substantially from CBT, coaching, mindfulness, and skills-based interventions.116,117 Best outcomes typically combine pharmacological and psychosocial approaches (multimodal treatment).82,14

28. What is CBT for ADHD and how effective is it?

CBT for ADHD is a structured, skills-based therapy targeting executive dysfunction, organization, planning, procrastination, distraction, and emotional regulation.115,116 Validated protocols include Safren’s Mastering Your Adult ADHD, Solanto’s Meta-Cognitive Therapy, and Ramsay/Rostain’s Cognitive-Behavioral Therapy for Adult ADHD.115,118,119 Randomized trials demonstrate moderate-to-large effects on ADHD symptoms (Hedges’ g ≈ 0.4–0.8) and executive function, with effects maintained at follow-up.114,120 CBT is most effective when added to medication.121

29. What is ADHD coaching and how is it different from therapy?

ADHD coaching focuses on practical, present/future-oriented goal-setting, accountability, and skills implementation rather than psychological insight or treatment of mental illness.122,123 Coaches help clients design routines, organizational systems, time-management strategies, and accountability structures.122 Research, while less abundant than for CBT, shows ADHD coaching improves self-regulation, well-being, executive function, and academic outcomes in college students and adults.124,125 Coaching is not a substitute for medical or psychotherapeutic treatment of comorbid mood/anxiety/trauma.123

30. Can mindfulness or meditation help with ADHD?

Mindfulness-Based interventions (MAPs for ADHD, MBCT) show small-to-moderate effects on attention, executive function, and emotional regulation in adults with ADHD in controlled trials and meta-analyses.126,127,128 A 2022 meta-analysis of 11 RCTs found mindfulness training improved ADHD symptoms (SMD ≈ 0.5) and emotion dysregulation, though effects on objective neuropsychological measures were smaller.128 Mindfulness is best framed as an adjunct, not a replacement, for medication and CBT.14

31. Does neurofeedback work for ADHD — what does the evidence say?

Neurofeedback (EEG biofeedback) has been studied extensively for ADHD with mixed results. Open-label and observational studies show benefits, but blinded sham-controlled trials show smaller or non-specific effects.129,130 A 2019 individual participant data meta-analysis found significant improvements on parent-rated, but not on probably-blinded measures.130 A 2022 meta-analysis of standard protocols (theta/beta, SCP) showed sustained effects 6–12 months post-treatment.131,132 European AAP and CADDRA guidelines recognize neurofeedback as a possible adjunct, but not first-line.14,112

32. What behavioral parent training programs help kids with ADHD?

Behavioral parent training is a strongly evidence-based intervention for children with ADHD, with effect sizes 0.4–0.7 on behavior and parenting outcomes.133,134 Validated programs include Russell Barkley’s Defiant Children, Triple P (Positive Parenting Program), Parent-Child Interaction Therapy (PCIT), Incredible Years, and the New Forest Parenting Programme.135,136,137 AAP and NICE guidelines recommend behavioral parent training as first-line for preschoolers (4–5 years) before considering medication.111,14

33. What classroom accommodations and IEP/504 supports help students with ADHD?

Common evidence-supported accommodations include preferential seating, extended test time, breaks, written/visual instructions, chunked assignments, fidget tools, organizational scaffolding, and behavior plans.138,139 Daily Report Cards linking school behavior to home rewards have strong evidence (DuPaul, Pfiffner).140 In the U.S., students with ADHD may qualify for 504 plans or IEPs (under “Other Health Impairment”) under IDEA, ensuring legally protected accommodations.141 Combined classroom-behavioral interventions improve academic performance and behavioral outcomes.142

34. Can exercise help ADHD symptoms?

Yes — both acute and regular aerobic exercise show benefits for attention, executive function, and behavior in children and adults with ADHD.143,144 A 2018 meta-analysis showed acute aerobic exercise improved attention/executive function, while regular exercise improved both core ADHD symptoms and comorbid anxiety/depression.145,146 Mechanisms include increased dopamine/norepinephrine, BDNF, and prefrontal-cortex blood flow.147 Exercise is recommended as an adjunct, not replacement, for evidence-based ADHD treatment.14

5. Daily Life, Productivity & Focus Strategies

35. How can adults with ADHD improve focus and concentration at work?

Evidence-supported workplace strategies include externalizing executive function: visible to-do lists, time-blocking, the Pomodoro technique (25-min focused intervals with breaks), single-tasking, body-doubling, and accountability partners.148,149 Reduce environmental distractions: noise-cancelling headphones, decluttered workspace, blocked websites/apps during deep-work blocks.150 Match task type to time-of-day energy patterns; tackle high-cognitive-demand work during peak focus windows.148 CBT-based ADHD workbooks (Safren, Solanto, Ramsay) provide structured implementation protocols.115,118,119

36. What are the best time management and organization strategies for ADHD?

Externalize time and tasks: use a single calendar (digital + visual), capture all commitments in one trusted system (paper planner or app like Todoist/TickTick), break projects into next-action steps, and review weekly.148,151 Use timers, alarms, and time-tracking apps to combat time blindness; build “buffer time” into estimates.30,31 Solanto’s Meta-Cognitive Therapy and Ramsay’s CBT protocol provide manualized organizational systems with proven outcomes.118,119 Visual cues (sticky notes, whiteboards) work better than internal reminders for ADHD brains.148

37. How do I stop procrastinating with ADHD?

ADHD-related procrastination stems from executive dysfunction (task initiation, working memory) and reward-system differences, not laziness.22,152 Effective strategies: break tasks into 5–10 minute next-actions, use implementation intentions (“if X then Y”), externalize accountability (body-doubling, deadlines, public commitments), reduce friction to start, manipulate environment, and use timers.148,153 CBT for ADHD specifically targets task-avoidance via behavioral activation and cognitive restructuring of perfectionism and overwhelm.115,118 Medication often dramatically reduces procrastination by improving task initiation.81

38. How does ADHD affect sleep, and what helps?

Up to 70% of children and 50–80% of adults with ADHD have sleep problems, including delayed sleep phase (later natural bedtime), insomnia, restless legs, sleep-disordered breathing, and non-restorative sleep.69,154 Treatment includes consistent sleep-wake schedule, morning bright light, evening blue-light reduction, CBT-Insomnia, exercise, melatonin (low dose 0.5–1 mg, 2–3 hours before desired sleep onset), and treating comorbid conditions.155,156 Stimulant timing matters — last dose 6–8 hours before bed for most patients.14

39. How do diet, sugar, and food additives affect ADHD?

Most rigorous research finds no strong evidence that sugar causes hyperactivity or ADHD symptoms in controlled trials.157 Some children show modest behavioral improvements when artificial food colorings are eliminated; the effect is small at the population level but meaningful for some sensitive individuals.158,159 Restrictive elimination diets show modest effects in subgroups but are difficult to maintain.158 Omega-3 supplementation (especially EPA-rich) shows small effects (SMD ≈ 0.2) and is a reasonable adjunct.160,161 A balanced whole-food diet supporting stable blood glucose, adequate protein at breakfast, and minimizing ultra-processed foods is sound general advice.162

40. Do screen time and social media make ADHD worse?

Excessive screen time, especially short-form video and social media, is associated with worsened attention, sleep, and mood — though directionality (cause vs effect) is debated.163,164 A JAMA 2018 study of adolescents found high-frequency digital media use was associated with later ADHD-symptom emergence, though effect sizes were modest.165 ADHD individuals are more vulnerable to problematic internet/gaming use due to dopaminergic reward differences.166,167 Practical guidance: limit recreational screens (especially before bed), use app blockers during work, and create non-screen alternatives for downtime.168

41. How does ADHD affect relationships, marriage, and parenting?

ADHD is associated with higher rates of relationship conflict, divorce, parenting stress, and intimate partner difficulties.169,170 Common patterns include the “parent-child dynamic” (non-ADHD partner takes on excessive executive function load), forgetfulness perceived as not caring, emotional reactivity, and missed commitments.171 Couples-based ADHD-informed therapy (Orlov’s The ADHD Effect on Marriage; Pera’s Is It You, Me, or Adult ADD?) and individual treatment (medication + CBT) significantly improve relationship outcomes.171,172 Parents with ADHD benefit from treatment, support, and adapted parenting strategies.173

42. How does ADHD impact career, finances, and executive function at work?

Untreated ADHD is associated with lower educational attainment, lower income, more job changes, higher unemployment, and higher rates of impulsive financial decisions, debt, and bankruptcy.174,175,176 Workplace impairments include missed deadlines, disorganization, interpersonal friction, and difficulty completing administrative tasks.177 Treatment (medication + coaching/CBT + workplace accommodations) significantly improves occupational outcomes.63,64 The U.S. ADA and Canadian human rights laws protect ADHD as a disability eligible for workplace accommodations.141

43. How can I support a partner, child, or employee with ADHD?

Educate yourself about ADHD as a neurobiological condition, not a character flaw.15,19 Externalize support: written reminders, shared calendars, visual cues, regular check-ins.148 Avoid criticism/shame; instead use specific, behavioral, non-attack feedback.178 Encourage professional treatment (medication, therapy, coaching).14 Offer body-doubling for tasks; break large projects into next-action steps.148 Normalize the use of accommodations.141 Take care of yourself — non-ADHD partners and parents benefit from their own support and education to avoid burnout.171,173

6. Special Topics, Lifespan & Comorbidities

44. How does ADHD present differently in women, and what are perimenopause/hormone effects?

Women with ADHD are more likely to present with inattentive symptoms, internalizing comorbidity (anxiety, depression), masking, and emotional dysregulation rather than overt hyperactivity.51,57 Estrogen modulates dopamine signaling — symptoms often worsen during the luteal phase, postpartum, and perimenopause/menopause when estrogen declines.59,179 Many women experience marked symptom intensification in their 40s–50s, sometimes leading to first-time diagnosis.60,180 Treatment may require dose adjustments aligned with hormonal cycles, and some studies suggest hormone therapy (HRT) may help cognitive symptoms in perimenopause when appropriate.181

45. What is the relationship between ADHD and substance use/addiction?

ADHD doubles to triples the risk of substance use disorders (SUDs), with 15–25% lifetime prevalence vs ~9% in general population.88,182 Hypothesized mechanisms include impulsivity, reward-system differences, self-medication of unrecognized symptoms, and shared genetic vulnerability.182,183 Importantly, treatment with stimulant medication is associated with reduced SUD risk, not increased risk.87,88 When ADHD and SUD co-occur, integrated treatment combining ADHD pharmacotherapy (sometimes preferring non-stimulants or long-acting stimulants), evidence-based addiction treatment, and CBT is recommended.184

46. How does ADHD affect emotional regulation and anger?

Emotional impulsivity and deficient emotional self-regulation (DESR) are core features of ADHD affecting up to 70% of adults, though not in DSM-5-TR criteria.33,34 Symptoms include short fuse, intense reactions to frustration, mood lability, low frustration tolerance, and difficulty calming down.35 Neuroimaging shows weaker prefrontal regulation of amygdala activation in ADHD.36 Treatment combines stimulants/guanfacine (which improve emotional regulation), CBT/DBT skills (mindfulness, distress tolerance, cognitive reappraisal), and lifestyle interventions (sleep, exercise).37,114

47. What is the link between ADHD and self-esteem, depression, and suicide risk?

People with ADHD experience elevated rates of low self-esteem, depression, anxiety, and suicidal ideation, partly due to chronic underachievement, repeated failure experiences (“the tape” of accumulated criticism), and comorbid mood disorders.185,186 Meta-analyses show 2–5× increased risk of suicide attempts in untreated ADHD; ADHD treatment is associated with significant reductions in suicidality.86,187 Comprehensive treatment addresses both ADHD and comorbid mood/anxiety, with safety planning where indicated.14

Crisis support: If you or someone you know is having thoughts of suicide, please reach out — in Canada call or text 9-8-8 (Suicide Crisis Helpline), in the U.S. call or text 988, or go to your nearest emergency department.

48. Does ADHD get better, worse, or stay the same with age?

Longitudinal research shows ADHD symptoms typically shift with age rather than disappear: hyperactivity often diminishes, while inattention, executive dysfunction, and emotional regulation difficulties persist into adulthood for the majority.188,189 Approximately 60–80% of childhood ADHD continues to cause functional impairment in adulthood, though only ~10–15% may meet full DSM criteria.189,190 Some adults experience symptomatic remission, others fluctuating courses; outcomes are improved by early diagnosis, sustained treatment, and supportive environments.191

49. Can lifestyle changes (sleep, exercise, nutrition, stress) actually reduce ADHD symptoms?

Lifestyle interventions are not curative but provide measurable additive benefits: regular aerobic exercise, prioritized sleep, balanced nutrition with adequate protein and omega-3s, stress management (mindfulness, yoga), and minimizing recreational screens all improve focus and emotional regulation.143,145,155,161 A 2017 review concluded lifestyle factors should be considered first-line adjuncts to medication and therapy.192 They are particularly valuable for milder cases, those declining medication, and as foundation for any treatment plan.14

50. What’s the difference between ADHD and autism, and can you have both (AuDHD)?

ADHD and autism spectrum disorder (ASD) are distinct neurodevelopmental conditions that frequently co-occur (estimates 30–80% overlap depending on sample).68,193 ASD is characterized by social communication differences and restricted/repetitive behaviors; ADHD by inattention, impulsivity, and hyperactivity.1 They share genetic risk variants, executive function challenges, and sensory sensitivities.194 Until DSM-5 (2013), they could not be co-diagnosed; now both diagnoses are routinely given when criteria are met (“AuDHD”). Treatment is individualized — stimulants help core ADHD symptoms in many autistic individuals but may worsen anxiety/sensory issues for others; assessment by a clinician familiar with both conditions is recommended.195,196

📚 References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). APA Publishing; 2022.
  2. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–499.
  3. Polanczyk G, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–948.
  4. Thomas R, et al. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4):e994–e1001.
  5. Song P, et al. The prevalence of adult attention-deficit hyperactivity disorder: a global systematic review and meta-analysis. J Glob Health. 2021;11:04009.
  6. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562–575.
  7. Larsson H, et al. The heritability of clinically diagnosed ADHD across the lifespan. Psychol Med. 2014;44(10):2223–2229.
  8. Demontis D, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51(1):63–75.
  9. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. 2007;96(9):1269–1274.
  10. Sciberras E, et al. Prenatal risk factors and the etiology of ADHD — review of existing evidence. Curr Psychiatry Rep. 2017;19(1):1.
  11. Hoogman M, et al. Subcortical brain volume differences in participants with ADHD across childhood and adulthood: a cross-sectional mega-analysis. Lancet Psychiatry. 2017;4(4):310–319.
  12. Volkow ND, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302(10):1084–1091.
  13. Sciberras E, et al. Family functioning and parenting of children with ADHD. JAACAP. 2011;50(11):1108–1117.
  14. National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline NG87. 2019 (updated 2024).
  15. Faraone SV, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818.
  16. Visser SN, et al. Trends in the parent-report of health care provider-diagnosed and medicated ADHD: United States, 2003–2011. JAACAP. 2014;53(1):34–46.
  17. Coghill D, Sonuga-Barke EJS. Annual research review: categories versus dimensions in classification and conceptualisation of child and adolescent mental disorders. J Child Psychol Psychiatry. 2012;53(5):469–489.
  18. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry. 1998;59(Suppl 7):50–58.
  19. Barkley RA. Taking Charge of Adult ADHD: Proven Strategies to Succeed at Work, at Home, and in Relationships. 2nd ed. Guilford Press; 2022.
  20. Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723.
  21. Biederman J, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524–540.
  22. Brown TE. Smart but Stuck: Emotions in Teens and Adults with ADHD. Jossey-Bass; 2014.
  23. Mannuzza S, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993;50(7):565–576.
  24. Sonuga-Barke EJS. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry. 2005;57(11):1231–1238.
  25. Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135–168.
  26. Miyake A, Friedman NP. The nature and organization of individual differences in executive functions: four general conclusions. Curr Dir Psychol Sci. 2012;21(1):8–14.
  27. Cortese S, et al. Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry. 2012;169(10):1038–1055.
  28. Barkley RA, et al. Time perception and reproduction in young adults with attention deficit hyperactivity disorder. Neuropsychology. 2001;15(3):351–360.
  29. Noreika V, Falter CM, Rubia K. Timing deficits in attention-deficit/hyperactivity disorder (ADHD): evidence from neurocognitive and neuroimaging studies. Neuropsychologia. 2013;51(2):235–266.
  30. Tuckman A. More Attention, Less Deficit: Success Strategies for Adults with ADHD. Specialty Press; 2009.
  31. Hallowell EM, Ratey JJ. Driven to Distraction (Revised): Recognizing and Coping with Attention Deficit Disorder. Anchor; 2011.
  32. Dodson W. Emotional regulation and rejection sensitivity in ADHD. ADDitude Magazine Clinical Reference; 2016 (Dodson is a board-certified psychiatrist who originated RSD as a clinical term).
  33. Barkley RA, Murphy KR. Deficient emotional self-regulation in adults with ADHD: the relative contributions of emotional impulsiveness and ADHD symptoms to adaptive impairments. J Psychopathol Behav Assess. 2010;32(2):157–173.
  34. Surman CB, et al. Deficient emotional self-regulation and adult attention deficit hyperactivity disorder: a family risk analysis. Am J Psychiatry. 2011;168(6):617–623.
  35. Shaw P, et al. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171(3):276–293.
  36. Hulvershorn LA, et al. Abnormal amygdala functional connectivity associated with emotional lability in children with ADHD. JAACAP. 2014;53(3):351–361.
  37. Mitchell JT, et al. A pilot trial of mindfulness meditation training for ADHD in adulthood: impact on core symptoms, executive functioning, and emotion dysregulation. J Atten Disord. 2017;21(13):1105–1120.
  38. Hupfeld KE, Abagis TR, Shah P. Living “in the zone”: hyperfocus in adult ADHD. Atten Defic Hyperact Disord. 2019;11(2):191–208.
  39. Ashinoff BK, Abu-Akel A. Hyperfocus: the forgotten frontier of attention. Psychol Res. 2021;85(1):1–19.
  40. Sergeant JA. Modeling attention-deficit/hyperactivity disorder: a critical appraisal of the cognitive-energetic model. Biol Psychiatry. 2005;57(11):1248–1255.
  1. Ramsay JR. Cognitive Behavioral Therapy for Adult ADHD: An Integrative Psychosocial and Medical Approach. 2nd ed. Routledge; 2017.
  2. Kooij JJS, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14–34.
  3. Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines. 4.1 ed. CADDRA; 2020.
  4. Pettersson R, et al. Diagnosing ADHD in adults: an examination of the discriminative validity of neuropsychological tests and diagnostic assessment instruments. J Atten Disord. 2018;22(11):1019–1031.
  5. Kessler RC, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–256.
  6. Conners CK, Erhardt D, Sparrow E. Conners’ Adult ADHD Rating Scales (CAARS). Multi-Health Systems; 1999.
  7. Wolraich ML, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol. 2003;28(8):559–567.
  8. Bussing R, et al. Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings. Assessment. 2008;15(3):317–328.
  9. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior Rating Inventory of Executive Function (BRIEF). Psychological Assessment Resources; 2000.
  10. Lahey BB, et al. Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. J Am Acad Child Adolesc Psychiatry. 1998;37(7):695–702.
  11. Quinn PO, Madhoo M. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. Prim Care Companion CNS Disord. 2014;16(3):PCC.13r01596.
  12. Nadeau KG, Littman EB, Quinn PO. Understanding Girls With AD/HD: How They Feel and Why They Do What They Do. 2nd ed. Advantage Books; 2015.
  13. Becker SP, et al. The internal, external, and diagnostic validity of sluggish cognitive tempo: a meta-analysis and critical review. JAACAP. 2016;55(3):163–178.
  14. Becker SP, Willcutt EG, et al. Report of a work group on sluggish cognitive tempo: key research directions and a consensus change in terminology to cognitive disengagement syndrome. JAACAP. 2023;62(6):629–645.
  15. Mowlem FD, et al. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. Eur Child Adolesc Psychiatry. 2019;28(4):481–489.
  16. Hinshaw SP, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: continuing impairment includes elevated risk for suicide attempts and self-injury. J Consult Clin Psychol. 2012;80(6):1041–1051.
  17. Williamson D, Johnston C. Gender differences in adults with attention-deficit/hyperactivity disorder: a narrative review. Clin Psychol Rev. 2015;40:15–27.
  18. Hinshaw SP, Nguyen PT, O’Grady SM, Rosenthal EA. Annual research review: ADHD in girls and women — underrepresentation, longitudinal processes, and key directions. J Child Psychol Psychiatry. 2022;63(4):484–496.
  19. Roberts B, et al. Sex hormones and the brain: implications for ADHD. J Atten Disord. 2018;22(13):1209–1218.
  20. Antoniou E, et al. Perimenopause and menopause in women with ADHD: a narrative review. Front Psychiatry. 2023;14:1183391.
  21. Biederman J, et al. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry. 2010;167(4):409–417.
  22. Asherson P, Buitelaar J, Faraone SV, Rohde LA. Adult attention-deficit hyperactivity disorder: key conceptual issues. Lancet Psychiatry. 2016;3(6):568–578.
  23. Jensen PS, et al. 3-year follow-up of the NIMH MTA study. JAACAP. 2007;46(8):989–1002.
  24. Halmøy A, et al. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment. J Atten Disord. 2009;13(2):175–187.
  25. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2006;256(Suppl 1):i26–i31.
  26. Larsson H, et al. ADHD and the risk for depression, anxiety and suicidal behavior: a systematic review and meta-analysis. J Affect Disord. 2013;151(1):1–16.
  27. DuPaul GJ, Gormley MJ, Laracy SD. Comorbidity of LD and ADHD: implications of DSM-5 for assessment and treatment. J Learn Disabil. 2013;46(1):43–51.
  28. Antshel KM, Russo N. Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. Curr Psychiatry Rep. 2019;21(5):34.
  29. Cortese S, et al. Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies. JAACAP. 2009;48(9):894–908.
  30. Spencer AE, et al. ADHD and trauma: a clinical review. Pediatr Clin North Am. 2016;63(5):837–856.
  31. Sciberras E, et al. Anxiety in children with ADHD: associations with sleep and academic outcomes. JAACAP. 2014;53(2):213–224.
  32. Biederman J, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with ADHD. Am J Psychiatry. 1993;150(12):1792–1798.
  33. Conway F, Oster M, Szymanski K. ADHD and complex trauma. Psychoanalytic Soc Work. 2011;18(1):60–72.
  34. Brown NM, et al. Associations between adverse childhood experiences and ADHD diagnosis and severity. Acad Pediatr. 2017;17(4):349–355.
  35. Moffitt TE, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry. 2015;172(10):967–977.
  36. Caye A, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood. JAMA Psychiatry. 2016;73(7):705–712.
  37. Wilens TE. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):32–37.
  1. Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28(2):121–129.
  2. Volkow ND, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.
  3. Pliszka SR, et al. Practice parameter for the assessment and treatment of children and adolescents with ADHD. JAACAP. 2007;46(7):894–921.
  4. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
  5. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–1086.
  6. Swanson JM, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. JAACAP. 2007;46(8):1015–1027.
  7. Chang Z, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry. 2014;71(3):319–325.
  8. Lichtenstein P, et al. Medication for attention deficit-hyperactivity disorder and criminality. NEJM. 2012;367(21):2006–2014.
  9. Chen Q, et al. Association between drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014;348:g3769.
  10. Wilens TE, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review. Pediatrics. 2003;111(1):179–185.
  11. Quinn PD, et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017;174(9):877–885.
  12. Cooper WO, et al. ADHD drugs and serious cardiovascular events in children and young adults. NEJM. 2011;365(20):1896–1904.
  13. Habel LA, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.
  14. Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2008;9(9):1565–1574.
  15. Storebø OJ, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD): Cochrane systematic review. BMJ. 2015;351:h5203.
  16. Carucci S, et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;120:509–525.
  17. Cortese S, et al. ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. Lancet Child Adolesc Health. 2020;4(6):412–414.
  18. Reed VA, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs. 2016;30(7):603–628.
  19. Sallee FR, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled trial. JAACAP. 2009;48(2):155–165.
  20. Swanson JM, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder. Clin Pharmacol Ther. 1999;66(3):295–305.
  21. Greenhill LL, et al. A comparison of immediate-release and extended-release amphetamine in children with attention-deficit hyperactivity disorder. JAACAP. 2003;42(11):1234–1241.
  22. Adler LA, et al. Efficacy and safety of lisdexamfetamine dimesylate in adults with ADHD. J Clin Psychiatry. 2008;69(9):1364–1373.
  23. Faraone SV, et al. Effect of stimulants on height and weight: a review of the literature. JAACAP. 2008;47(9):994–1009.
  24. Michelson D, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112–120.
  25. Jain R, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. JAACAP. 2011;50(2):171–179.
  26. Nasser A, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2020;42(8):1452–1466.
  27. Verbeeck W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;10:CD009504.
  28. Cohen JM, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol. 2017;130(6):1192–1201.
  29. Huybrechts KF, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations. JAMA Psychiatry. 2018;75(2):167–175.
  30. Bro SP, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139–147.
  31. Hale TW. Hale’s Medications and Mothers’ Milk. 19th ed. Springer Publishing; 2020.
  32. ACOG Committee on Practice Bulletins—Obstetrics. ACOG Committee Opinion: Use of psychiatric medications during pregnancy and lactation. 2008 (reaffirmed).
  33. Greenhill LL, et al. Stimulant medications. JAACAP. 1996;35(11):1397–1409.
  34. Wolraich ML, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD in children and adolescents. Pediatrics. 2019;144(4):e20192528.
  35. Bélanger SA, et al. ADHD in children and youth: Part 2 — treatment. Paediatr Child Health. 2018;23(7):462–472.
  36. Adler LA, Newcorn JH. Administering and evaluating the response to ADHD treatment in adults. J Clin Psychiatry. 2011;72(1):e02.
  37. Knouse LE, Teller J, Brooks MA. Meta-analysis of cognitive-behavioral treatments for adult ADHD. J Consult Clin Psychol. 2017;85(7):737–750.
  1. Safren SA, et al. Mastering Your Adult ADHD: A Cognitive-Behavioral Treatment Program — Therapist Guide. 2nd ed. Oxford University Press; 2017.
  2. Safren SA, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA. 2010;304(8):875–880.
  3. Young Z, Moghaddam N, Tickle A. The efficacy of cognitive behavioral therapy for adults with ADHD: a systematic review and meta-analysis of randomized controlled trials. J Atten Disord. 2020;24(6):875–888.
  4. Solanto MV. Cognitive-Behavioral Therapy for Adult ADHD: Targeting Executive Dysfunction. Guilford Press; 2011.
  5. Ramsay JR, Rostain AL. The Adult ADHD Tool Kit: Using CBT to Facilitate Coping Inside and Out. Routledge; 2014.
  6. Solanto MV, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry. 2010;167(8):958–968.
  7. Emilsson B, et al. Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC Psychiatry. 2011;11:116.
  8. Kubik JA. Efficacy of ADHD coaching for adults with ADHD. J Atten Disord. 2010;13(5):442–453.
  9. Ahmann E, et al. A descriptive review of ADHD coaching research: implications for college students. J Postsecond Educ Disabil. 2018;31(1):17–39.
  10. Field S, et al. Assessing the impact of ADHD coaching services on university students’ learning skills, self-regulation, and well-being. J Postsecond Educ Disabil. 2013;26(1):67–81.
  11. Parker DR, et al. Self-control in postsecondary settings: students’ perceptions of ADHD college coaching. J Atten Disord. 2013;17(3):215–232.
  12. Zylowska L, et al. Mindfulness meditation training in adults and adolescents with ADHD: a feasibility study. J Atten Disord. 2008;11(6):737–746.
  13. Cairncross M, Miller CJ. The effectiveness of mindfulness-based therapies for ADHD: a meta-analytic review. J Atten Disord. 2020;24(5):627–643.
  14. Poissant H, et al. Mindfulness-based interventions for adult ADHD: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2020;16:735–747.
  15. Arns M, et al. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity — a meta-analysis. Clin EEG Neurosci. 2009;40(3):180–189.
  16. Riesco-Matías P, et al. What do meta-analyses have to say about the efficacy of neurofeedback applied to children with ADHD? Review of previous meta-analyses and a new meta-analysis. J Atten Disord. 2021;25(4):473–485.
  17. Van Doren J, et al. Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2019;28(3):293–305.
  18. Enriquez-Geppert S, et al. EEG-neurofeedback as a tool to modulate cognition and behavior: a review tutorial. Front Hum Neurosci. 2017;11:51.
  19. Daley D, et al. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. JAACAP. 2014;53(8):835–847.
  20. Coates J, et al. Parenting interventions for ADHD: a systematic literature review and meta-analysis. J Atten Disord. 2015;19(10):831–843.
  21. Barkley RA. Defiant Children: A Clinician’s Manual for Assessment and Parent Training. 3rd ed. Guilford Press; 2013.
  22. Sanders MR, et al. The Triple P-Positive Parenting Program: a systematic review and meta-analysis of a multi-level system of parenting support. Clin Psychol Rev. 2014;34(4):337–357.
  23. Sonuga-Barke EJS, et al. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. JAACAP. 2001;40(4):402–408.
  24. DuPaul GJ, Stoner G. ADHD in the Schools: Assessment and Intervention Strategies. 3rd ed. Guilford Press; 2014.
  25. Pfiffner LJ, DuPaul GJ. Treatment of ADHD in school settings. In: Barkley RA, ed. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 4th ed. Guilford Press; 2015:596–629.
  26. Owens JS, et al. A daily report card intervention for elementary students with ADHD. School Ment Health. 2012;4(3):142–155.
  27. DuPaul GJ, Weyandt LL, Janusis GM. ADHD in the classroom: effective intervention strategies. Theory Pract. 2011;50(1):35–42.
  28. Fabiano GA, et al. A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. Clin Psychol Rev. 2009;29(2):129–140.
  29. Den Heijer AE, et al. Sweat it out? The effects of physical exercise on cognition and behavior in children and adults with ADHD: a systematic literature review. J Neural Transm. 2017;124(Suppl 1):3–26.
  30. Ng QX, et al. The effect of physical exercise on adult ADHD: a systematic review and meta-analysis. Children (Basel). 2017;4(8):68.
  31. Cerrillo-Urbina AJ, et al. The effects of physical exercise in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis of randomized control trials. Child Care Health Dev. 2015;41(6):779–788.
  32. Vysniauske R, et al. The effects of physical exercise on functional outcomes in the treatment of ADHD: a meta-analysis. J Atten Disord. 2020;24(5):644–654.
  33. Ratey JJ. Spark: The Revolutionary New Science of Exercise and the Brain. Little, Brown; 2008.
  34. Solanto MV. The efficacy of CBT in adult ADHD: structuring the chaos through external scaffolding. Curr Atten Disord Rep. 2013;5(3):258–264.
  35. Kessler RC, et al. The effects of temporally secondary co-morbid mental disorders on the associations of DSM-IV ADHD with adverse outcomes in the U.S. National Comorbidity Survey Replication. Psychol Med. 2014;44(8):1779–1792.
  36. Wendt FR, et al. Multivariate genome-wide analysis of educational attainment, intelligence, and ADHD. Mol Psychiatry. 2021;26(11):6691–6701.
  37. Allen D. Getting Things Done: The Art of Stress-Free Productivity. Revised ed. Penguin Books; 2015.
  38. Niermann HCM, Scheres A. The relation between procrastination and symptoms of attention-deficit hyperactivity disorder (ADHD) in undergraduate students. Int J Methods Psychiatr Res. 2014;23(4):411–421.
  39. Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: a meta-analysis of effects and processes. Adv Exp Soc Psychol. 2006;38:69–119.
  40. Bijlenga D, Vollebregt MA, Kooij JJS, Arns M. The role of the circadian system in the etiology and pathophysiology of ADHD: time to redefine ADHD? Atten Defic Hyperact Disord. 2019;11(1):5–19.
  1. Hvolby A. Associations of sleep disturbance with ADHD: implications for treatment. Atten Defic Hyperact Disord. 2015;7(1):1–18.
  2. Bijlenga D, et al. Sleep disturbances in adults with ADHD: a systematic review and meta-analysis. Sleep Med Rev. 2019;46:124–135.
  3. Wolraich ML, Wilson DB, White JW. The effect of sugar on behavior or cognition in children: a meta-analysis. JAMA. 1995;274(20):1617–1621.
  4. Nigg JT, et al. Meta-analysis of attention-deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. JAACAP. 2012;51(1):86–97.
  5. Pelsser LM, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377(9764):494–503.
  6. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. JAACAP. 2011;50(10):991–1000.
  7. Chang JP, et al. Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology. 2018;43(3):534–545.
  8. Heilskov Rytter MJ, et al. Diet in the treatment of ADHD in children — a systematic review of the literature. Nord J Psychiatry. 2015;69(1):1–18.
  9. Twenge JM, Campbell WK. Associations between screen time and lower psychological well-being among children and adolescents: evidence from a population-based study. Prev Med Rep. 2018;12:271–283.
  10. Tamana SK, et al. Screen-time is associated with inattention problems in preschoolers: results from the CHILD birth cohort study. PLoS One. 2019;14(4):e0213995.
  11. Ra CK, et al. Association of digital media use with subsequent symptoms of attention-deficit/hyperactivity disorder among adolescents. JAMA. 2018;320(3):255–263.
  12. Yen JY, et al. The comorbid psychiatric symptoms of internet addiction: ADHD, depression, social phobia, and hostility. J Adolesc Health. 2007;41(1):93–98.
  13. Carli V, et al. The association between pathological internet use and comorbid psychopathology: a systematic review. Psychopathology. 2013;46(1):1–13.
  14. American Academy of Pediatrics. Media and young minds. Pediatrics. 2016;138(5):e20162591.
  15. Wymbs BT, et al. Rate and predictors of divorce among parents of youths with ADHD. J Consult Clin Psychol. 2008;76(5):735–744.
  16. Eakin L, et al. The marital and family functioning of adults with ADHD and their spouses. J Atten Disord. 2004;8(1):1–10.
  17. Orlov M. The ADHD Effect on Marriage: Understand and Rebuild Your Relationship in Six Steps. Specialty Press; 2010.
  18. Pera G. Is It You, Me, or Adult A.D.D.? Stopping the Roller Coaster When Someone You Love Has Attention Deficit Disorder. 1201 Alarm Press; 2008.
  19. Theule J, et al. Parenting stress in families of children with ADHD: a meta-analysis. J Emot Behav Disord. 2013;21(1):3–17.
  20. Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. MedGenMed. 2006;8(3):12.
  21. Klein RG, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012;69(12):1295–1303.
  22. Beauchaine TP, et al. Comorbidities and continuities as ontogenic processes: toward a developmental spectrum model of externalizing psychopathology. Dev Psychopathol. 2010;22(4):735–770.
  23. Gjervan B, et al. Functional impairment and occupational outcome in adults with ADHD. J Atten Disord. 2012;16(7):544–552.
  24. Pera G, Robin AL, eds. Adult ADHD-Focused Couple Therapy: Clinical Interventions. Routledge; 2016.
  25. de Jong M, et al. ADHD symptoms across the menstrual cycle: a systematic review. Arch Womens Ment Health. 2023;26(3):385–399.
  26. Camara B, et al. Attention-deficit/hyperactivity disorder medication in pregnant and postpartum women. JAMA Psychiatry. 2017;74(4):444–445.
  27. Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women’s Health Initiative 10 years on. Climacteric. 2012;15(3):256–262.
  28. Wilens TE, et al. ADHD and substance use disorders. Annu Rev Med. 2008;59:335–344.
  29. Ottosen C, et al. Sex differences in comorbidity patterns of attention-deficit/hyperactivity disorder. JAACAP. 2019;58(4):412–422.
  30. Crunelle CL, et al. International consensus statement on screening, diagnosis, and treatment of substance use disorder patients with comorbid attention-deficit/hyperactivity disorder. Eur Addict Res. 2018;24(1):43–51.
  31. Mazzone L, et al. Self-esteem evaluation in children and adolescents suffering from ADHD. Clin Pract Epidemiol Ment Health. 2013;9:96–102.
  32. Harpin V, et al. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2016;20(4):295–305.
  33. Septier M, et al. Association between suicidal spectrum behaviors and attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2019;103:109–118.
  34. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–165.
  35. Sibley MH, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. Am J Psychiatry. 2022;179(2):142–151.
  36. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. Guilford Press; 2008.
  37. Cherkasova MV, et al. Developmental course of attention deficit hyperactivity disorder and its predictors. J Can Acad Child Adolesc Psychiatry. 2013;22(1):47–54.
  38. Nigg JT. Annual research review: on the relations among self-regulation, self-control, executive functioning, effortful control, cognitive control, impulsivity, risk-taking, and inhibition for developmental psychopathology. J Child Psychol Psychiatry. 2017;58(4):361–383.
  39. Leitner Y. The co-occurrence of autism and attention deficit hyperactivity disorder in children — what do we know? Front Hum Neurosci. 2014;8:268.
  40. Rommelse NN, et al. Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry. 2010;19(3):281–295.
  41. Ghirardi L, et al. The familial co-aggregation of ASD and ADHD: a register-based cohort study. Mol Psychiatry. 2018;23(2):257–262.
  42. Sokolova E, et al. A causal and mediation analysis of the comorbidity between attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). J Autism Dev Disord. 2017;47(6):1595–1604.

Need Personalized ADHD Support?

Dr Samuel offers comprehensive ADHD assessment, evidence-based therapy, executive function coaching, and neurofeedback for children, adolescents, and adults. Treatment plans are individualized and integrate medication consultation, CBT, lifestyle, and family/couples support.

Book a Consultation